Hercules is a biopharmaceutical company developing an innovative, oral, non-toxic drug therapy for chronic treatment of patients with Triple Negative Breast Cancer, an aggressive form of cancer that does not respond well to treatment with existing targeted therapies.
We have found evidence that blocking the Aryl hydrocarbon Receptor in epithelial cancer could
- Enhance the response of the immune system to cancer
- Reduce the chance of future relapses by reducing the number of Cancer Stem Cells
- Reduce metastatic behavior
- Reduce agression of existing cancer
- Make cancer cells more sensitive to standard chemotherapy
Hercules has discovered novel anti-cancer drugs that block the Aryl Hydrocarbon receptor and is now testing these products in preparation for clinical trials.
Apart from breast cancer, Hercules' products also have potential as treatment of other agressive cancers like glioblastoma, oral cancers and pancreatic cancer.
Triple Negative Breast Cancer
Breast cancer is the most common invasive cancer in women affecting 1 in 8 woman during their lifetime. Approximately 80% of breast cancer patients express one or more of three critical mediators of cell growth: the estrogen receptor, the progesterone receptor, and the HER2/Neu epidermal growth factor receptor 2.
These patients can now be treated with drugs that target one of these receptors. However, approximately 20% of patients do not express these receptors. They have so-called “Triple Negative Breast Cancer”, and their only treatment option is non-specific chemotherapy, radiation and surgery.
In many cases Triple Negative Breast Cancer relapses because of persistent cancer stem cells.